Julian has extensive investment banking experience, with over $200 billion of completed transactions across a range of healthcare subsectors, including pharmaceuticals, biotechnology, medical devices, diagnostics, IT and services. He advises clients on M&A, equity and debt offerings, de-mergers and divestitures for public, private and private equity companies. Before joining us at Canaccord Genuity, Julian was CEO of BSML Inc, a US NASDAQ-listed medical technology company, which he successfully led through fundraisings and a strategic exit. He is a qualified medical doctor from Guy’s Hospital in London and received his MBBS and BSc (Hons) from London University.

Rupert has advised on over 50 transactions in life sciences, across subsectors including biopharmaceuticals, specialty pharma, tools and diagnostics, and med tech. His deal experience includes IPOs, secondary and private financings, as well as numerous cross-border public and private M&A. Before joining Canaccord Genuity in April 2016, Rupert spent 10 years at Piper Jaffray as a senior calling officer and two years at ING in healthcare investment banking. He began his career at harmaVentures, a specialist consultancy servicing the life sciences industry. Rupert holds a Masters degree in Biochemistry from the University of Oxford and the ACCA Diploma in Financial Management.

Stephen has 30 years’ experience in the pharmaceuticals and biotechnology sectors, as a senior executive in the sector, a strategic consultant, a VC and a senior corporate financier with Barings and Warburg. As CFO of Oxford GlycoSciences Plc he was responsible for the largest follow-on fundraising in the sector in the UK and also set up a joint venture with Marconi PLC, Confirmant Limited, to create personalised medicine solutions based on OGS’s proteome database. Stephen is Non-Executive Chairman of Silence Therapeutics plc and Sareum Holdings PLC. He has a DPhil from Oxford University and an MBA from City University Business School.

Howard joined Canaccord Genuity in January 2016. From 2000 to 2007 he worked at Teather & Greenwood/Landsbanki, becoming Head of Research in 2004. There he provided equity research on UK-listed pharmaceutical, biotech, diagnostic and medical device businesses, and was lead analyst on multiple IPOs and ECM transactions. In 2007, Howard joined Oakes, Lyman & Co Limited, working with their portfolio of companies on financing and strategy. He was appointed CFO and Executive Director of orthopaedic regenerative medicine businesses at CellCoTec in 2010 and Orteq Limited in 2014, and managed the operational merger of the two businesses as well as multiple financings.

Samuel joined Canaccord Genuity in January 2015. His research focuses on small and mid-cap Healthcare companies. Samuel joined us from Ernst & Young LLP, where he spent four years, most recently as an executive within audit and assurance services. He is an Associate of the Institute of Chartered Accountants and has passed all CFA examinations. Samuel holds a BSc in Biology with Management from the University of London Imperial College of Science, Technology and Medicine.